Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis Giles

Showing results (11-20 of 174) with videos related to

Pageof 18
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Challenges in Opening and Enrolling Patients in Clinical TrialsJulie M Vose, Meredith K Chuk, Francis Giles
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.
Expert Opinion on Pharmacotherapy|May 22, 2013
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Ciara Freeman, Niamh Keane, Ronan Swords, et al.
Cancer Journal (Sudbury, Mass.)|November 23, 2007
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatmentElias Jabbour, Jorge Cortes, Francis Giles, et al.
European Journal of Haematology|September 30, 2020
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myelomaKatie R Ryan, Francis Giles, Gareth J Morgan
Future Oncology (London, England)|June 4, 2008
Current status of therapy for chronic myeloid leukemia: a review of drug developmentSwami Padmanabhan, Saritha Ravella, Tyler Curiel, et al.
Seminars in Thrombosis and Hemostasis|July 1, 2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disordersAlfonso Quintás-Cardama, Hagop M Kantarjian, Francis Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Important therapeutic targets in chronic myelogenous leukemiaHagop M Kantarjian, Francis Giles, Alfonso Quintás-Cardama, et al.
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Idrugs : the Investigational Drugs Journal|July 21, 2007
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyondElias Jabbour, Jorge Cortes, Francis Giles, et al.
Pageof 18

Showing results (11-20 of 174) with videos related to

Sort By:
Pageof 18
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Challenges in Opening and Enrolling Patients in Clinical TrialsJulie M Vose, Meredith K Chuk, Francis Giles
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.
Expert Opinion on Pharmacotherapy|May 22, 2013
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Ciara Freeman, Niamh Keane, Ronan Swords, et al.
Cancer Journal (Sudbury, Mass.)|November 23, 2007
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatmentElias Jabbour, Jorge Cortes, Francis Giles, et al.
European Journal of Haematology|September 30, 2020
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myelomaKatie R Ryan, Francis Giles, Gareth J Morgan
Future Oncology (London, England)|June 4, 2008
Current status of therapy for chronic myeloid leukemia: a review of drug developmentSwami Padmanabhan, Saritha Ravella, Tyler Curiel, et al.
Seminars in Thrombosis and Hemostasis|July 1, 2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disordersAlfonso Quintás-Cardama, Hagop M Kantarjian, Francis Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Important therapeutic targets in chronic myelogenous leukemiaHagop M Kantarjian, Francis Giles, Alfonso Quintás-Cardama, et al.
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Idrugs : the Investigational Drugs Journal|July 21, 2007
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyondElias Jabbour, Jorge Cortes, Francis Giles, et al.
Pageof 18